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Abstract
Introduction Although some studies have suggested that
gemcitabine delivered as a fixed dose rate (FDR) infusion
of 10 mg/m2/min could be more effective than when
administered as the standard 30-min infusion, the available
pharmacokinetic data are still too limited to draw definitive
conclusions. This study is aimed to investigate the plas-
matic and intracellular pharmacokinetics of gemcitabine
given as FDR at doses of 600 and 1,200 mg/m2 in combina-
tion with 75 mg/m2 of cisplatin in advanced non-small-cell
lung cancer (NSCLC) patients.
Patients and method The patients were divided into two
groups receiving different initial doses of the drug: 4
patients received 600 mg/m2 gemcitabine 60-min i.v.
infusion and 4 patients 1,200 mg/m2 gemcitabine 120-min
i.v. infusion both as a FDR of 10 mg/m2/min on days 1 and
8 of a 21-day cycle (at first cycle). At the second cycle, all
patients were treated with gemcitabine at 1,200 mg/m2
120-min i.v. infusion (FDR of 10 mg/m2/min) on days 1
and 8 of a 21-day cycle. At each cycle, gemcitabine was
administered alone on day one, and in combination with
75 mg/m2 of cisplatin on day 8. Plasmatic and intracellular
pharmacokinetic analyses were performed on blood
samples collected at defined time points before, during and
after gemcitabine infusion.
Results The plasmatic pharmacokinetic parameters were
clearly different when the patients received a higher gem-
citabine dose in the second cycle compared to the lower
dose of the first course; in the same time, the intracellular
drug levels were not modified. Comparing the pharmaco-
kinetic parameters of different patients treated at different
dose levels, the results appeared to be quite similar.
Conclusions A substantially higher accumulation of
metabolites in peripheral blood mononuclear cells was
observed when the longer infusion time was employed,
suggesting a pharmacological advantage for this treatment
schedule.
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Introduction
Gemcitabine, 20,20-difluoro-20-deoxycytidine (dFdC) is a
pyrimidine antimetabolite, with a broad spectrum of anti-
tumor activity [1], representing one of the reference drugs
in combination chemotherapy of non-small-cell lung can-
cer (NSCLC) [2].
Gemcitabine is a pro-drug that enters the cell by means
of nucleoside transporters and becomes active through an
intracellular transformation catalyzed by deoxycytidine
kinase to the final triphosphate form (dFdCTP) in a rate-
limiting reaction [1, 3, 4]. Gemcitabine pharmacokinetics in
humans are characterized by rapid elimination and exten-
sive deamination to its inactive 20,20-difluorodeoxyuridine
(dFdU) that is the main metabolite present in plasma [3, 4].
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Gemcitabine is usually administered intravenously as a
30-min infusion at the dose of 1,000–1,200 mg/m2, but
previous studies suggest that under these conditions, the
formation of dFdCTP in normal peripheral blood mono-
nuclear cells (PBMC) is saturated when gemcitabine con-
centrations of 15–20 lM are achieved in plasma [3, 4].
Gemcitabine delivered as a fixed dose rate (FDR) infusion
of 10 mg/m2/min has been suggested to be more effective
than when administered as the standard 30-min infusion
[3–5]. This schedule seems adequate for maintenance of
the plasma target level for a longer period of time [5, 6],
but the available pharmacokinetic data are still too limited
to draw definitive conclusions.
In terms of clinical outcomes, the picture is unclear. For
example, in pancreatic cancer, despite the promising results
from a randomized phase II study showing a survival
advantage for patients treated with FDR infusion [5], a
more recent report failed to confirm the same advantage for
FDR infusion that led an increased toxicity [7].
We have therefore conducted a phase II study in
advanced NSCLC patients, aimed to investigate the phar-
macokinetics of gemcitabine and dFdU administered as a
FDR of 10 mg/m2/min at doses of 600 and 1,200 mg/m2 in
combination with 75 mg/m2 of cisplatin.
Methods
Patients, study design and objectives
On the basis of results from our previous dose-escalating
study with cisplatin and gemcitabine administered at 7
different dose levels (from 600 to 1,200 mg/m2) [8] as
prolonged FDR in advanced NSCLC, we planned to
explore both the plasmatic and intracellular pharmacoki-
netics of gemcitabine at the lower (600 mg/m2) and higher
(1,200 mg/m2) levels of dose.
From July 2005 to February 2006, we enrolled 8 patients
affected by advanced NSCLC and treated at the Depart-
ment of Oncology of Santa Chiara Hospital, Trento, Italy.
The treatment schedule was planned to evaluate both intra-
and inter-patient pharmacokinetic variability of gemcita-
bine given as a prolonged FDR infusion in combination
with cisplatin.
According to the study plan, the patients were divided
into two groups receiving different initial doses of the drug:
4 patients treated with 600 mg/m2 gemcitabine 60-min i.v.
infusion (Group A), and 4 patients treated with 1,200 mg/m2
gemcitabine 120-min i.v. infusion (Group B), both at FDR of
10 mg/m2/min on days 1 and 8 of a 21-day cycle (at first
cycle). At the second cycle, all patients received 1,200 mg/m2
gemcitabine 120-min i.v. infusion (FDR of 10 mg/m2/min) on
days 1 and 8 of a 21-day cycle.
At each cycle, gemcitabine was administered alone on
day one and in combination with 75 mg/m2 of cisplatin on
day 8. Cisplatin was infused for 30 min, immediately
before the administration of gemcitabine.
All patients, in absence of progressive disease, received
further 4 courses of gemcitabine 1,200 mg/m2 on days 1
and 8 plus cisplatin 75 mg/m2 on day 8 for a total number
of 6 cycles: in these courses, no pharmacokinetic analyses
were planned.
All of the patients gave their written informed consent to
participate in the study, which was approved by the local
Ethics Committee.
Pharmacokinetic study
Blood samples were collected at the following times: pre-
infusion, 15 and 30 min during the infusion, at the end of the
infusion, 30 min, 2, 4, and 24 h after the end of the infusion.
Blood was withdrawn by venipuncture, immediately
placed into heparinized tubes containing 50 lL of the
cytidine deaminase inhibitor tetrahydrouridine (10 mg/mL,
in bi-distilled water) (Calbiochem, La Jolla, CA, USA) to
prevent the spontaneous deamination of gemcitabine to
dFdU and placed in an ice bath until following separation
of plasma and PBMC. After centrifugation at 4C for
10 min at 2,500 rpm, the plasma fraction was separated
and stored frozen at -20C until analysis of gemcitabine
and dFdU. Then the cellular fraction, kept at 4C, was
suspended (1:1) with phosphate buffered saline (PBS) and
layered over 5 ml Ficoll-Hypaque (Pharmacia, Stockholm,
Sweden) (specific gravity 1.077 g/mL) (2:1 v/v) and cen-
trifuged at 1,000 g for 25 min at 4C. The buffy coat
containing PBMC was collected, washed twice with 20 mL
ice-cold PBS (4C) and centrifuged at 400 g for 8 min at
4C. Finally, the cell pellet was resuspended in 110 lL
PBS. An aliquot of 10 lL of the suspension was used to
determine the cell number by automatic coulter counter
system. The rest of the suspension was immediately stored
at -40 C until shipping and analysis.
The determination of the plasma concentrations of
gemcitabine and dFdU was performed by using the
recently published method based on HPLC coupled to mass
spectrometry [9].
The concentration of dFdCTP in PBMC cells was
determined by HPLC (lowest sensitivity limit 0.25 mg/L)
as described by Kirstein et al. [10] and Huang et al. [11] for
chromatographic conditions and final sample preparation
following deproteinization, respectively.
Pharmacokinetic analysis
Gemcitabine and dFdU pharmacokinetic parameters were
calculated with WinNonLin Pro Node 4.1 pharmacokinetic
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software (Pharsight Co., Mountain View, CA, USA) by
using a non-compartmental approach.
Statistical analysis
Two-tailed t test was used to determine the significance of
differences between measurements of dFdCTP values.
Results
Patients’ characteristics
The patients’ (6 men and 2 women) median age was
61.5 years (range 34–69). All tumors were adenocarci-
noma. Three patients achieved a partial response, while 5
patients experienced progressive disease. All patients
relapsed with a median progression-free survival of three
months (range 1–7 months); the median survival was
4.5 months (range 2–34). Grade 3–4 haematological tox-
icities were observed only in two patients of group A
during the second course of therapy.
Pharmacokinetic data
Plasma pharmacokinetics
Gemcitabine Cmax values were in the range 10–20 lM,
approximately at the end of the constant rate infusion of 60
or 120 min in all the patients, in all courses monitored.
After the end of infusion, gemcitabine concentrations rap-
idly declined from plasma with a T1/2 of less than 30 min.
Gemcitabine was detectable up to 4 h post infusion at
concentrations close to the limit of quantitation (Table 1).
Table 1 reports the means and standard deviations of the
main pharmacokinetic parameters of gemcitabine and
dFdU.
Cellular pharmacokinetics
A wide interpatient variability in dFdCTP peak concen-
trations was observed (data not shown) (Table 2).
In both the groups, the mean peak concentrations of
dFdCTP in PBMC were higher on day 8 of the first cycle
of treatment when compared to day 1 of the same cycle of
treatment. In both cases, the difference was not statistically
significant.
In group A, the mean peak concentrations of dFdCTP
after the infusion of 1,200 mg/m2 gemcitabine during a
120-min period were similar at day 1 and day 8 of the cycle
2. Within this group of patients, a slight increase in the
peak levels of dFdCTP was observed at day 1 of cycle 2
when compared to day 1 of cycle 1.
In Group B, the mean dFdCTP peak concentration was
similarly increased, albeit not significantly, at day 8 when
compared to day 1 of the second cycle. An increase in
mean peak dFdCTP concentrations was also noted at day 1
and 8 of cycle 2 when compared to the same days of cycle
1 in group B.
Intergroup variations were also observed. In group B
patients, the intracellular concentrations of dFdCTP were
significantly or nearly significantly higher than corre-
sponding values in group A patients.
Peak dFdCTP concentrations occurred within a wide
interval of time ranging from 15 min after the start of
gemcitabine infusion and 4 h after the end of it, indepen-
dently of its duration (60 or 120 min). No significant
variations in Tmax among cycles and days of treatment were
observed within each group of patients. A trend to a later
occurrence of the dFdCTP peak concentration was
observed in patients of group B when compared to those of
group A.
Planned comparisons
The comparison of pharmacokinetic parameters between
different patients receiving two different dose levels in the
first course showed a significant difference in terms of
gemcitabine Cmax (23.8 vs. 18.7; P = 0.01) and AUCexp
(7.7 vs. 10.5; P = 0.005) on day 1 and in terms of intra-
cellular peak concentration on day 8 (173.0 vs. 316.9;
P = 0.009). The same comparison within patients treated
with two different dose levels in the first two chemotherapy
courses showed that both gemcitabine AUCexp and dFdU
pharmacokinetic parameters were significantly higher
when the patients received the higher dose in the second
course (data not shown). No differences were observed
assessing the differences in patients who received the same
dose in the first two courses of gemcitabine.
Discussion
Gemcitabine is one of the most widely used anticancer
drugs and is usually administered at the dose of 1,000–
1,200 mg/m2 over 30-min infusion. However, in recent
years, several studies have tested both different infusion
durations and drug doses to optimize the relationship
between the drug delivery and anticancer activity. Since
the intracellular metabolic conversion of gemcitabine is
limited by saturation of the deoxycytidine kinase activity
occurring at low-dose level, the 10 mg/m2/min FDR infu-
sion could enhance the drug antitumor activity [5, 12].
In our previous study we observed an apparent dose-
dependent gemcitabine pharmacokinetics [8]. Between 600
and 1,200 mg/m2, the drug plasma levels appeared to be
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not related to the doses. The critical level of 15 lM, nec-
essary to exert the pharmacological activity [3, 4], was
achieved and maintained successfully in the majority of
patients treated at the low or middle doses, but surprisingly,
not in patients treated at the high doses. To clarify these
surprising findings, we evaluated the intra- and inter-
patient differences in plasmatic and intracellular gemcita-
bine pharmacokinetics when the drug was administered at
two different doses as FDR.
As a result, the target plasma concentration of 15 lM
was successfully achieved in all patients treated with
600 mg/m2 and in 14/16 of those treated with 1,200 mg/m2.
The pharmacokinetic parameters were clearly different
when the patients received a higher gemcitabine dose in the
second cycle compared to the lower dose of the first course,
confirming that, in this case, the intra-patient variability
was mainly due to the dose level; in the same time, the
intracellular drug levels were not modified, as expected by
the FDR administration system. Comparing the pharma-
cokinetic parameters of different patients treated at dif-
ferent dose levels, the results appeared to be quite similar:
in this case, the inter-patient variability may have a role in
masking the effect of the different dose levels.
Various studies have evaluated intracellular dFdCTP
concentrations in PBMC after gemcitabine treatment in
patients with solid tumors [5, 13–16]. However, it is dif-
ficult to compare our results with those of the literature
because the published studies were performed administer-
ing gemcitabine at variable doses and with variable infu-
sion times. When a standard 30-min infusion was
Table 1 Main pharmacokinetic parameters of gemcitabine and dFdU in NSCLC patients
Day 1 Day 8
Cmax
(lM)
AUCexp
(lg*h/mL)
AUCinf
(lg*h/mL)
T1/2
(min)
Cmax
(lM)
AUCexp
(lg*h/mL)
AUCinf
(lg*h/mL)
T1/2
(min)
Gemcitabine
Group A (n = 4)
Course 1 (600 mg/m2) Mean 23.8 7.7 7.7 19 22.5 6.4 – –
SD 2.5 1 1 6.7 4.1 1.46 – –
CV (%) 10.5 13 13 35.2 18.2 22.9 – –
Course 2 (1,200 mg/m2) Mean 34.5 17.1 17.1 27.8 27.5 14.4 14.4 19
SD 20 5.8 5.8 6.6 5 2.3 2.3 6.6
CV (%) 58.8 33.9 33.9 23.7 18.2 15.7 15.8 33.9
Group B (n = 4)
Course 1 (1,200 mg/m2) Mean 18.7 10.5 10.5 19.9 21.2 10.4 11.5 21.2
SD 1.9 0.8 0.8 6.9 7.1 3.2 3 6.1
CV (%) 10 7.8 7.8 34.8 33.4 31.2 26.1 28.6
Course 2 (1,200 mg/m2) Mean 17.8 9.2 9.3 23.7 21.6 1.1 – –
SD 4.1 2.7 3.4 13.3 12.5 5 – –
CV (%) 22.6 30.1 36.4 56.1 57.7 45.5 – –
dFdU
Group A (n = 4)
Course 1 (600 mg/m2) Mean 90.7 215.2 269.1 10.7 89.2 204 281.3 13.4
SD 10.3 31.8 57.9 2.4 17.2 33.7 75.7 5.8
CV (%) 11.4 14.8 21.5 22.7 19.3 16.5 26.9 43.1
Course 2 (1,200 mg/m2) Mean 138.5 346.7 436.3 10.2 162.8 329.6 371.1 8.3
SD 31.6 84.6 177.9 4.7 55.2 96.2 105.7 1
CV (%) 22.9 24.4 40.8 45.8 33.9 29.2 28.5 12.2
Group B (n = 4)
Course 1 (1,200 mg/m2) Mean 94.8 220.3 253.6 7.1 99.6 214.5 255 10.3
SD 32.2 136.8 154.7 3.2 35.5 81 92.6 2.9
CV (%) 34 62.1 61 45.6 35.7 37.8 36.3 28.1
Course 2 (1,200 mg/m2) Mean 94.1 194.8 232.9 10 88.8 215.2 271.9 11.5
SD 19.4 43.9 58 2.3 15.5 37.5 47.1 3.3
CV (%) 20.6 22.6 24.9 23 17.5 17.4 17.3 28.6
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employed, gemcitabine doses ranged from 800 to
2,200 mg/m2 [5, 13–16]. When gemcitabine was adminis-
tered as a FDR infusion of 10 mg/m2/min, infusion times
ranged from 75 to 150 min [5, 16]. Although in our study
FDR was the same, the infusion times were different, i.e.
60 and 120 min.
The increase in the accumulation of dFdCTP in PBMC
that occurred at day 8 when compared to day 1 in almost all
treatment conditions may have been due to enzyme
induction, particularly of deoxycytidine kinase necessary
for gemcitabine phosphorylation, that is an activation
reaction allowing the drug to be incorporated into DNA
and exert its therapeutic action in cells [17]. The admin-
istration of cisplatin before that of gemcitabine at day 8
of each cycle might have also played a relevant role in
the induction of deoxycytidine kinase. The ability of
cisplatin to induce nucleotide excision repair processes
may up-regulate several enzymes, including deoxycytidine
kinase, needed to increase deoxyribonucleotides levels
(e.g. dFdCTP) [13]. They also reported a similar trend to
increased dFdCTP concentrations in white blood cells in
patients with solid tumors treated with a gemcitabine–cis-
platin combination although with a longer interval (24 h)
between platinum and gemcitabine.
In our study, only a slight increase in PBMC dFdCTP
concentrations occurred at cycle 2 when compared to cycle
1 in both patient groups and both days of treatment with the
exception of day 8 in group A patients. These variations
were, however, not statistically significant. No evidence of
dFdCTP accumulation was observed by De Lange et al.
[15] as a function of courses and days of treatment.
In group B patients undergoing a longer time of FDR
drug infusion (120 min), the intracellular concentrations of
dFdCTP were substantially higher when compared to group
A patients receiving the same fixed dose rate for a shorter
infusion time (60 min).
Similar results were also reported by Tempero et al. [5]
for an identical FDR infusion of gemcitabine lasting
150 min versus a standard 30-min infusion of a higher
gemcitabine dose (2,200 mg/m2). In a cohort of patients
receiving gemcitabine at different dose rates (1,000 mg/m2
over a standard 30-min infusion on week 1 and over 150-
min infusion on week 2) Patel et al. [14] reported a Cmax of
dFdCTP at the end of infusion (150 min), which was
higher than the plateau levels achieved after the 30-min
infusion. An investigation by Soo et al. [16] comparing a
combination of carboplatin and gemcitabine at standard
rate or fixed dose rate infusion in patients with advanced
stage NSCLC reported similar AUC of intracellular
dFdCTP in both treatment arms even though the dose of
gemcitabine was higher in the standard rate arm (1,000 mg/
m2 over 30 min vs. 750 mg/m2 over 75 min).
Although the activation mechanisms of gemcitabine are
well-known in terms of metabolic pathways, some aspects
are relevant for future developments. Several studies have
underlined that gemcitabine activity could be related to
specific polymorphisms in the deoxycytidine kinase, cyti-
dine deaminase, and/or gemcitabine transporter genes
[18]. Moreover, gemcitabine may have anticancer activity
also when it is administered at very low doses and with
an infusion rate much lower than the well-known level
of 10 mg/m2/min: the drug delivered at 250 mg/m2 in
Table 2 Mean intracellular peak concentrations and Tmax of dFdCTP in peripheral blood mononuclear cells
Day 1 Day 8 (with cisplatin)
Peak concentrations
(pmol 9 106 cells)
Tmax
(min)
Peak concentrations
(pmol 9 106 cells)
Tmax
(min)
Group A (n = 4)
Course 1 (600 mg/m2) Mean 92.6* 150 173.0** 105
SD 85.9 117.5 29.5 130.8
CV (%) 92.7 78.3 17 124.5
Course 2 (1,200 mg/m2) Mean 158.1 101.3 140.1*** 150
SD 134.7 172.5 98.5 60
CV (%) 85.2 170.4 70.3 40
Group B (n = 4)
Course 1 (1,200 mg/m2) Mean 273.5* 191.3 316.9** 142.5
SD 139.5 145.6 69.7 155.6
CV (%) 51 76.1 22 109.2
Course 2 (1,200 mg/m2) Mean 335.5 243.8 445.3*** 195
SD 117.5 162.7 210.5 139.6
CV (%) 35 66.7 47.3 71.6
* P \ 0.05; ** P \ 0.01; *** P \ 0.001
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360-min infusion has in fact been demonstrated to be active
in NSCLC patients [19, 20] and in bladder cancer patients
[21].
In conclusion, several pharmacokinetic and clinical
studies suggested that gemcitabine has a complex phar-
macological profile, where the transporter proteins play a
central role able to influence the drug activity. In this view,
data from the present study, although obtained from a very
limited sample of patients, may be of value for future
researches covering a wider range of clinically useful dose
rates of gemcitabine with a better exploitation of its acti-
vating pharmacokinetic and metabolic mechanisms.
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